Integrated BioPharma — Q3 2026 Earnings Summary

Integrated BioPharma, Inc. reported revenue of $9.9 million for the quarter ended September 30, 2026, a 22% decrease from the $12.7 million recorded in the same period of 2025. The company posted an operating loss of $1.0 million and a net loss of approximately $0.7 million, or $0.02 per share, compared to an operating income of $0.2 million and net income of $0.1 million in the prior year quarter. Revenue concentration remained high, with the two largest customers in the Contract Manufacturing Segment accounting for approximately 88% of total revenue in the current quarter.